Inactive Instrument

News GALA BIOP Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Mar. 28	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update	Mar. 28	AQ
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : SELLAS Life Sciences Group, Inc. - Special Call	Mar. 26
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study	Mar. 26	AQ
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	Mar. 26	CI
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET	Mar. 19	AQ
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 15	MT
Top Midday Decliners	Mar. 15	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	Mar. 15	MT
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall	Mar. 15	MT
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	Mar. 15	AQ
SELLAS Life Sciences Group, Inc. announced a financing transaction	Mar. 14	CI
SELLAS Life Sciences : Material Event - Form 8-K	Mar. 11	PU
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships	Mar. 08	AQ
SELLAS Life Sciences Group, Inc. Announces Executive Changes	Mar. 08	CI
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference	Mar. 01	AQ
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time	Feb. 29	AQ
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget	Feb. 06	AQ
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference	Jan. 25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer